v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 165,810 $ 26,676
Short-term investments – available for sale 539,929 875,936
Prepaid clinical trial and preclinical study costs 8,053 3,476
Prepaid expenses and other current assets 1,806 1,128
Total current assets 715,598 907,216
Right-of-use assets 85 1,003
Deferred financing costs 0 56
Deposits 46 46
Total assets 715,729 908,321
Current liabilities:    
Accounts payable 53,251 9,813
Other accrued liabilities 23,279 17,111
Lease liability, current 137 489
Total current liabilities 76,667 27,413
Lease liability, net of current portion 0 630
Total long-term liabilities 0 630
Total liabilities 76,667 28,043
Commitments and contingencies (Note 10)
Stockholders’ equity:    
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024 1 1
Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024 0 0
Additional paid-in capital 1,486,229 1,368,972
Accumulated deficit (847,546) (487,907)
Accumulated other comprehensive loss 378 (788)
Total stockholders’ equity 639,062 880,278
Total liabilities and stockholders’ equity $ 715,729 $ 908,321